Arman Oruc

Arman Oruc

PartnerCo-Chair, Antitrust + Competition

Arman Oruc is co-chair of the firm’s Antitrust and Competition practice. He specializes in antitrust related issues, including regulatory clearance and approval of mergers and acquisitions, government investigations, antitrust litigation, and antitrust risks associated with strategic business practices. Arman was most recently part of the founding team of a life sciences company, helping grow the start-up into a late-stage clinical platform company. Arman’s experience in both merger clearance and antitrust litigation, combined with his in-house experience, gives him a unique perspective in his practice.


Arman has advised on antitrust issues associated with countless consummated and proposed transactions for private equity and public company clients. He has shepherded transactions through the FTC, DOJ, and competition authorities outside of the US. His litigation experience includes single company monopolization cases, allegations of abuse of intellectual property, standard setting activities, foreclosure allegations, as well as successful amnesty applications in cartel investigations.

Representative matters in the last two years:

  • Versanis Bio and its obesity asset in the acquisition by Eli Lilly for up to $1.925 billion
  • Inversago Pharma and its obesity asset in the acquisition by Novo Nordisk for $1.07 billion
  • EQRx in its acquisition by Revolution Medicines
  • Nimbus Therapeutics in its sale of Allosteric Tyk2 Inhibitor Program to Takeda for $4 billion upfront and up to $6 billion total following antitrust litigation against Celgene and Bristol Myers Squibb to enjoin their attempted acquisition of the same program
  • A leading company in the fashion industry in multi-jurisdictional cartel investigation
  • Essex Property (REIT) in MDL involving alleged price fixing in residential rentals involving pricing algorithm by RealPage
  • Software developer Rainmaker in alleged pricing fixing case involving pricing algorithm for hotel room rates
  • Quince Therapeutics in its acquisition by EryDel SpA
  • Flagship Pioneering in its investment in Evelo Biosciences
  • Surface Oncology in its acquisition by Coherus BioSciences
  • Haystack Oncology in its acquisition by Quest Diagnostics
  • TCR² Therapeutics in its acquisition by Adaptimmune Therapeutics
  • Moderna its strategic collaboration with Generation Bio to develop non-viral genetic therapies
  • Concert Pharmaceuticals in its acquisition by Sun Pharmaceutical for $576 million and contingent value rights
  • Entrada Therapeutics in its collaboration with Vertex Pharmaceuticals on EEV-Therapeutics for $250 million in equity and upfront payments, and up to $485 million in milestone payments
  • Webster Equity Partners in its three concurrent transactions in Corium Pharma Solutions, Corium Therapeutics and Radius Health
  • Forma Therapeutics on its acquisition by Novo Nordisk for $1.1 billion
  • MiroBio in its acquisition by Gilead Sciences for $405 million
  • Orna Therapeutics in its license and collaboration agreement with Merck
  • Deliverr in its sale to Shopify for $2.1 billion
  • Checkmate Pharmaceuticals in its sale to Regeneron Pharmaceuticals for approximately $250 million
  • BridgeBio Pharma in its strategic collaboration with Helsinn Healthcare S.A. to develop and co-commercialize BridgeBio’s GPX4 inhibitor in multiple cancer tumor types
  • Citrix Systems in its definitive agreement under which affiliates of Vista Equity Partners, and Evergreen Coast Capital Corporation, an affiliate of Elliott Investment Management L.P., will acquire Citrix for $16.5 billion
  • BioDelivery Sciences International, Inc. in its acquisition by Collegium Pharmaceutical for $604 million
  • Ampersand Capital Partners in its sale of Nexelis Group, Inc. to Q2 Solutions, a wholly owned subsidiary of IQVIA, Inc.
  • Audacious Inquiry on its acquisition by PointClickCare Technologies
  • Trillium Therapeutics in its sale to Pfizer for $2.26 billion

Past litigation matters include:

  • Co-counsel for Weyerhaeuser in the seminal monopsonization litigations*
  • Lead counsel for Staples in antitrust litigations and government investigations related to product design and strategy issues surrounding private label ink cartridges compatible with HP-branded printers*
  • Lead counsel for Ericsson in a Sherman Act challenge brought by “positioning” technology company whose technology was excluded from the 4G standard*
  • Lead antitrust counsel to the standard-setting organization through the format war between HD DVD and Blu-ray technologies*
  • Represented MasterCard in numerous antitrust litigations against the DOJ, American Express, Discover and Visa*

*Denotes experience prior to joining Goodwin.

Professional Experience

Arman serves on Law360’s Editorial Advisory Board for Life Sciences.

Prior to joining Goodwin, Arman was part of the founding team of Biosplice Therapeutics Inc. where he served as the Chief Legal Officer and a member of the Board. Prior to Biosplice, Arman practiced as an antitrust lawyer for seventeen years during which he helped launch Simpson Thacher & Bartlett’s Washington, D.C. office and expand the firm’s merger review and antitrust litigation practices.




University of California, Berkeley


Cambridge University


Skidmore College



  • California
  • New York
  • District of Columbia


  • U.S. District Court for the Southern District of New York
  • U.S. District Court for the Eastern District of New York
  • U.S. District Court for the District of Columbia
  • U.S. Court of Appeals for the Second Circuit
  • U.S. Court of Appeals for the District of Columbia Circuit

Recognition & Awards

In 2023, Arman was recognized by JD Supra Readers' Choice Awards for his thought leadership in Antitrust & Trade Regulation.

Arman has been selected for inclusion in The Legal 500 US 2023 where clients note that he “is a first class antitrust lawyer” who is “measured in his communication, has a strong understanding of the big picture, logically designs and articulates his case, and can go deep into the clinical science to support his legal case.” In 2022, Arman was recognized by LMG Life Sciences as a “Life Sciences Star.”



Speaking Engagements

  • Speaker, “Mergers: Private equity in the spotlight,” GCR Live: Law Leaders Global 2023, February 1, 2023
  • Speaker, “Biden Administration Merger Challenges: Can the Agencies Turn Around a Losing Record?” 2023 Goodwin CLE Day Webinar Series, January 19, 2023
  • Speaker, “What’s Happening at the FTC and Its Impact on Life Sciences Deal Flow,” Goodwin Fourth Annual JPMorgan Symposium, January 11, 2023
  • Speaker, “Goodwin’s Closing the Deal – How to get a Private Equity Deal Done in an Environment of Heightened Antitrust Scrutiny Webinar,” October 26, 2022
  • Speaker, “Dealing in an era of fast evolving innovation: Deals, M&A, and Alliances,” KPMG 2022 Global Life Sciences Summit, May 18, 2022
  • Speaker, “#BigTechBreakUp: What’s to Come in Antitrust for the Tech Sector in 2022,” 2022 Goodwin CLE Day Webinar Series, January 26, 2022
  • Speaker, “Fireside Chat: Antitrust Expansion in Life Sciences Collaborations,” Goodwin's Third Annual JPMorgan Symposium, January 13, 2022
  • Speaker, “FTC Antitrust Lessons Learned for Life Sciences Companies,” Goodwin Life Sciences Disputes Webinar Series, November 18, 2021